Affectis Pharmaceuticals Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Affectis Pharmaceuticals General Information


Developer of drugs for the treatment of psychiatric and inflammatory disorders. The company discovers and develops drugs based on findings in the fields of depression, schizophrenia and inflammation.

Contact Information

Formerly Known As
NeuroNova AG
Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Parent Company
LDC Beteiligungen
Primary Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
+49 0231 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Affectis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 07-Jan-2014 000.00 Completed Generating Revenue
7. Later Stage VC (Series D) 22-Mar-2010 00.00 000.00 Completed Generating Revenue
6. Grant 08-Jul-2009 00000 0000 Completed Generating Revenue
5. Later Stage VC (Series C) 24-Oct-2006 000.00 0000 Completed Startup
4. Grant 18-Oct-2005 00.000 00.00 Completed Startup
3. Early Stage VC (Series B) 13-Apr-2005 00.00 00.00 Completed Startup
2. Grant 31-Jan-2005 $982K $4.65M Completed Startup
1. Early Stage VC (Series A) 10-Nov-2003 $4.65M $4.65M Completed Startup
To view Affectis Pharmaceuticals’s complete valuation and funding history, request access »

Affectis Pharmaceuticals Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adamant Biomedical Investment Minority 000 0000 000000 0
Aescap Life Sciences Mutual Fund Minority 000 0000 000000 0
Bayern Kapital Venture Capital Minority 000 0000 000000 0
EMBL Ventures Venture Capital Minority 000 0000 000000 0
KfW IPEX-Bank Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »